Tokyo Tape
Sign in
← Terumo

Quarterly report · Q2

4543.TEDINET S100PLTQ
Period2022-04-01 → 2022-09-30
Filed2022-11-14
StandardIFRS
ConsolidatedYes
Data checks16 of 16 passed
Key figures · 61
MetricValuePeriodScopeSource row
Revenue¥403.3bn2022-04-01 → 2022-09-30Cons.Revenue IFRS
Revenue¥206.0bn2022-07-01 → 2022-09-30dCons.Revenue IFRS
Revenue¥703.3bn2021-04-01 → 2022-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥344.6bn2021-04-01 → 2021-09-30Cons.Revenue IFRS
Revenue¥172.9bn2021-07-01 → 2021-09-30dCons.Revenue IFRS
Operating income¥56.0bn2022-04-01 → 2022-09-30Cons.Operating profit loss IFRS
Operating income¥25.5bn2022-07-01 → 2022-09-30dCons.Operating profit loss IFRS
Operating income¥65.9bn2021-04-01 → 2021-09-30Cons.Operating profit loss IFRS
Operating income¥29.6bn2021-07-01 → 2021-09-30dCons.Operating profit loss IFRS
Profit before tax¥54.6bn2022-04-01 → 2022-09-30Cons.Profit loss before tax IFRS
Profit before tax¥25.0bn2022-07-01 → 2022-09-30dCons.Profit loss before tax IFRS
Profit before tax¥114.5bn2021-04-01 → 2022-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax¥65.3bn2021-04-01 → 2021-09-30Cons.Profit loss before tax IFRS
Profit before tax¥29.3bn2021-07-01 → 2021-09-30dCons.Profit loss before tax IFRS
Net income (owners)¥40.3bn2022-04-01 → 2022-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥17.9bn2022-07-01 → 2022-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥88.8bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)¥50.0bn2021-04-01 → 2021-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)¥22.1bn2021-07-01 → 2021-09-30dCons.Profit loss attributable to owners of parent IFRS
Net income¥40.3bn2022-04-01 → 2022-09-30Cons.Profit loss IFRS
Net income¥17.9bn2022-07-01 → 2022-09-30dCons.Profit loss IFRS
Net income¥50.0bn2021-04-01 → 2021-09-30Cons.Profit loss IFRS
Net income¥22.1bn2021-07-01 → 2021-09-30dCons.Profit loss IFRS
Total assets¥1.66Tat 2022-09-30Cons.Assets IFRS
Total assets¥1.47Tat 2022-03-31Cons.Assets IFRS
Total assets¥1.37Tat 2021-09-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥487.8bnat 2022-09-30Cons.Liabilities IFRS
Total liabilities¥461.4bnat 2022-03-31Cons.Liabilities IFRS
Net assets / equity¥1.17Tat 2022-09-30Cons.Equity IFRS
Net assets / equity¥1.01Tat 2022-03-31Cons.Equity IFRS
Net assets / equity¥904.0bnat 2021-09-30Cons.Equity IFRS
Net assets / equity¥856.7bnat 2021-03-31dCons.Equity IFRS
Equity (owners)¥1.17Tat 2022-09-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥1.01Tat 2022-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥904.0bnat 2021-09-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥212.6bnat 2022-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥205.3bnat 2022-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥202.9bnat 2021-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥200.8bnat 2021-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥60.3bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥141.5bn2021-04-01 → 2022-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥66.7bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥31.6bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥78.5bn2021-04-01 → 2022-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥40.5bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥37.9bn2022-04-01 → 2022-09-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥70.9bn2021-04-01 → 2022-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥25.1bn2021-04-01 → 2021-09-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥53.372022-04-01 → 2022-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥23.752022-07-01 → 2022-09-30dCons.Basic earnings loss per share IFRS
EPS (basic)¥117.452021-04-01 → 2022-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥66.112021-04-01 → 2021-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥29.222021-07-01 → 2021-09-30dCons.Basic earnings loss per share IFRS
EPS (diluted)¥53.352022-04-01 → 2022-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥23.742022-07-01 → 2022-09-30dCons.Diluted earnings loss per share IFRS
EPS (diluted)¥117.382021-04-01 → 2022-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥66.072021-04-01 → 2021-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥29.22021-07-01 → 2021-09-30dCons.Diluted earnings loss per share IFRS
Equity ratio70.6%at 2022-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio68.7%at 2022-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio66.0%at 2021-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 20
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue external2022-04-01 → 2022-09-30¥124m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-09-30¥275m
jpcrp040300-q2r_E01630-000Blood And Cell Technologies Companyreportable segmentrevenue external2022-04-01 → 2022-09-30¥74.0bn
jpcrp040300-q2r_E01630-000Blood And Cell Technologies Companyreportable segmentsegment profit2022-04-01 → 2022-09-30¥9.1bn
jpcrp040300-q2r_E01630-000Cardiac And Vascular Companyreportable segmentrevenue external2022-04-01 → 2022-09-30¥235.4bn
jpcrp040300-q2r_E01630-000Cardiac And Vascular Companyreportable segmentsegment profit2022-04-01 → 2022-09-30¥52.9bn
jpcrp040300-q2r_E01630-000Medical Care Solutions Companyreportable segmentrevenue external2022-04-01 → 2022-09-30¥93.8bn
jpcrp040300-q2r_E01630-000Medical Care Solutions Companyreportable segmentsegment profit2022-04-01 → 2022-09-30¥8.1bn
—segment totalrevenue external2022-04-01 → 2022-09-30¥403.2bn
—segment totalsegment profit2022-04-01 → 2022-09-30¥70.2bn
Reconciling Itemsreconcilingrevenue external2021-04-01 → 2021-09-30¥124m
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-09-30−¥1.8bn
jpcrp040300-q2r_E01630-000Blood And Cell Technologies Companyreportable segmentrevenue external2021-04-01 → 2021-09-30¥58.2bn
jpcrp040300-q2r_E01630-000Blood And Cell Technologies Companyreportable segmentsegment profit2021-04-01 → 2021-09-30¥11.8bn
jpcrp040300-q2r_E01630-000Cardiac And Vascular Companyreportable segmentrevenue external2021-04-01 → 2021-09-30¥194.3bn
jpcrp040300-q2r_E01630-000Cardiac And Vascular Companyreportable segmentsegment profit2021-04-01 → 2021-09-30¥50.8bn
jpcrp040300-q2r_E01630-000Medical Care Solutions Companyreportable segmentrevenue external2021-04-01 → 2021-09-30¥92.0bn
jpcrp040300-q2r_E01630-000Medical Care Solutions Companyreportable segmentsegment profit2021-04-01 → 2021-09-30¥13.4bn
—segment totalrevenue external2021-04-01 → 2021-09-30¥344.5bn
—segment totalsegment profit2021-04-01 → 2021-09-30¥76.0bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 696
ItemContextValueUnit
Other financial assets ca IFRSCurrentQuarterInstant290000000JPY
Inventories ca IFRSPrior1YearInstant198536000000JPY
Inventories ca IFRSCurrentQuarterInstant235316000000JPY
Income taxes receivable ca IFRSPrior1YearInstant778000000JPY
Income taxes receivable ca IFRSCurrentQuarterInstant918000000JPY
Other current assets ca IFRSPrior1YearInstant18086000000JPY
Other current assets ca IFRSCurrentQuarterInstant24446000000JPY
Current assets other than assets held for sale ca IFRSPrior1YearInstant558713000000JPY
Current assets other than assets held for sale ca IFRSCurrentQuarterInstant618039000000JPY
Assets held for sale IFRSPrior1YearInstant－JPY
Assets held for sale IFRSCurrentQuarterInstant5331000000JPY
Current assets IFRSPrior1YearInstant558713000000JPY
Current assets IFRSCurrentQuarterInstant623370000000JPY
Property plant and equipment IFRSPrior1YearInstant333864000000JPY
Property plant and equipment IFRSCurrentQuarterInstant368399000000JPY
Goodwill and intangible assets IFRSPrior1YearInstant514801000000JPY
Goodwill and intangible assets IFRSCurrentQuarterInstant582932000000JPY
Investments accounted for using equity method IFRSPrior1YearInstant4133000000JPY
Investments accounted for using equity method IFRSCurrentQuarterInstant3725000000JPY
Other financial assets nca IFRSPrior1YearInstant25937000000JPY
Other financial assets nca IFRSCurrentQuarterInstant41665000000JPY
Deferred tax assets IFRSPrior1YearInstant20198000000JPY
Deferred tax assets IFRSCurrentQuarterInstant22424000000JPY
Other non current assets nca IFRSPrior1YearInstant16043000000JPY
Other non current assets nca IFRSCurrentQuarterInstant16414000000JPY
Non current assets IFRSPrior1YearInstant914979000000JPY
Non current assets IFRSCurrentQuarterInstant1035561000000JPY
Assets IFRSPrior1YearInstant1473693000000JPY
Assets IFRSCurrentQuarterInstant1658931000000JPY
Trade and other payables cl IFRSPrior1YearInstant81545000000JPY
Trade and other payables cl IFRSCurrentQuarterInstant82344000000JPY
Bonds and borrowings cl IFRSPrior1YearInstant1121000000JPY
Bonds and borrowings cl IFRSCurrentQuarterInstant11324000000JPY
Other financial liabilities cl IFRSPrior1YearInstant7228000000JPY
Other financial liabilities cl IFRSCurrentQuarterInstant7414000000JPY
Income taxes payable cl IFRSPrior1YearInstant14104000000JPY
Income taxes payable cl IFRSCurrentQuarterInstant19951000000JPY
Provisions cl IFRSPrior1YearInstant499000000JPY
Provisions cl IFRSCurrentQuarterInstant395000000JPY
Other current liabilities cl IFRSPrior1YearInstant73222000000JPY
Other current liabilities cl IFRSCurrentQuarterInstant80055000000JPY
Liabilities other than liabilities directly associated with assets held for sale IFRSPrior1YearInstant177721000000JPY
Liabilities other than liabilities directly associated with assets held for sale IFRSCurrentQuarterInstant201485000000JPY
Liabilities directly associated with assets held for sale IFRSPrior1YearInstant－JPY
Liabilities directly associated with assets held for sale IFRSCurrentQuarterInstant776000000JPY
Total current liabilities IFRSPrior1YearInstant177721000000JPY
Total current liabilities IFRSCurrentQuarterInstant202261000000JPY
Bonds and borrowings ncl IFRSPrior1YearInstant224875000000JPY
Bonds and borrowings ncl IFRSCurrentQuarterInstant228344000000JPY
Other financial liabilities ncl IFRSPrior1YearInstant30297000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 16 of 16 passed
balance sheet identityconsolidated 2022-03-31pass rounding
balance sheet identityconsolidated 2022-09-30pass
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2021-07-01/2021-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-09-30pass
statement vs summary · net income attributable to parentconsolidated 2022-07-01/2022-09-30pass
statement vs summary · operating cash flowconsolidated 2021-04-01/2021-09-30pass
statement vs summary · operating cash flowconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2021-04-01/2021-09-30pass
statement vs summary · revenueconsolidated 2021-07-01/2021-09-30pass
statement vs summary · revenueconsolidated 2022-04-01/2022-09-30pass
statement vs summary · revenueconsolidated 2022-07-01/2022-09-30pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-09-30pass